Lead investigational program, NDV-01, for High-Grade Non-Muscle Invasive Bladder Cancer, is being evaluated in a Phase 2 study. In addition, preparations are underway to advance sepranolone, a Phase ...

Adaptogens Market is Segmented by Type (Organic, Synthetic), by Application (Food and Beverages, Nutraceuticals, ...

Summit Therapeutics highlights China approval of Akeso's ivonescimab for NSCLC, with enrollment ongoing for Phase 3 HARMONi-7 ...

Indivior PLC’s recovery hinges on Sublocade’s momentum and market trends, though risks persist in litigation and earnings.

Complete response (CR) observed in 79% (26/33) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Inductio ...

In parallel, Portage is advancing the dose escalation of PORT-6, a potent and selective inhibitor of the A2A adenosine receptor. Portage's plan is to ultimately co-administer PORT-6 with PORT-7 in the ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

Transplanting bacteria from the feces of healthy people into the guts of mice and patients with fibromyalgia successfully ...

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that on April 23, 2025, the European Commission (EC) granted marketing authorization to VYJUVEK ® (beremagene geperpavec-svdt) for ...

Jonathan Rockoff is the Health Business editor at The Wall Street Journal, managing a team that reports on pharmaceutical and biotechnology companies, health insurers and hospitals. During the ...

At a laboratory in Austria's mountainous Tyrol province, scientists are DNA testing about 100 honey samples a month to learn about their composition—and in some cases to determine whether they have ...